Bortezomib - First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature.
CONCLUSION: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices. PMID: 32234004 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 4, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Increased NID1 Expression among Breast Cancer Lung Metastatic Women; A Comparative Analysis between Naive and Treated Cases.
CONCLUSIONS: The increased expression of NID1 in early to advanced naive as compared to the treated groups with Lung metastasis makes it a promising marker which has pro-metastatic role in Breast cancer. PMID: 32116201 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 4, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Feasibility of Repurposing Clioquinol for Cancer Therapy.
CONCLUSION: Clioquinol exhibits anti-cancer activities in many cancer types preclinically. Low therapeutic efficacy in a clinical trial has prompted new studies that aim in discovering more effective clioquinol-based cancer therapies. PMID: 32106803 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - March 1, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

The Molecular Docking of Flavonoids Isolated from Daucus carota as a Dual Inhibitor of MDM2 and MDMX.
CONCLUSION: Thus the compound7 can be used for the revival of p53 signaling pathway function however, intensive in vitro and in vivo experiments are required to prove the in silico analysis. PMID: 32101134 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 28, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
CONCLUSION: Selectively targeting HDAC6 over other subtypes represents two fold advantages: maximize the pharmacological effects and minimize the side effects seen in pan-HDAC inhibitors. Many small molecule selective HDAC6 inhibitors have advanced to clinical studies in recent years. We anticipate the approval of selective HDAC6 inhibitors as therapeutic agents in near future. PMID: 32065106 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 20, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

SOX4 Serves an Oncogenic Role in the Tumourigenesis of Human Breast Adenocarcinoma by Promoting Cell Proliferation, Migration and Inhibiting Apoptosis.
In this study, we explored the effects of sex-determining region Y-box 4 (SOX4) protein on the proliferation, migration, apoptosis and tumourigenesis of breast adenocarcinoma and its possible mechanisms. METHODS: The SOX4 overexpression or knockdown michigan cancer foundation-7 (MCF-7) cell lines were established. Among the SOX4 overexpression or MCF-7 knockdown cell lines, the proliferation, migration ability and apoptosis rate were detected. The expression levels of apoptosis-related proteins (Bax and Cleaved caspase-3) were analysed using Western blot. The effect of SOX4 on tumourigenesis was analysed using the clon...
Source: Recent Patents on Anti-Cancer Drug Discovery - February 14, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Alkaloids as Anticancer Agents: A Review of Chinese Patents in Recent 5 Years.
Conclusion: Many newly found alkaloids displayed potent anticancer activity both in vitro and in vivo, and some of the anticancer alkaloids acted as protein kinase inhibitors or CDK inhibitors possess potential for developing as novel anticancer agents. PMID: 32003702 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 1, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Toward a Personalized Use of Paclitaxel.
Authors: Russo GL PMID: 31920185 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 12, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Expression of B Cell Translocation Gene 1 Protein in Colon Carcinoma and its Clinical Significance.
In this study, we investigated the expression of BTG1 protein in colon cancer, and its association with clinicopathology and prognosis. METHODS: The tumor specimens from 59 patients with colon cancer who had undergone radical colectomy were selected as the observation group. Para-carcinoma tissues from the same patients were selected as the control group. The expression of BTG1 mRNA and protein in the specimen of two groups were analyzed by quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) and Western blot. According to the immunohistochemical results, the patients were divided into BTG1-negative and BTG1-posi...
Source: Recent Patents on Anti-Cancer Drug Discovery - January 11, 2020 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Lentiviral-Mediated Beclin-1 Overexpression Inhibits Cell Proliferation and Induces Autophagy of Human Esophageal Carcinoma Eca109 Cell Xenograft in Nude Mice.
CONCLUSION: BECLIN-1 can induce autophagy in esophageal carcinoma Eca109 cells, and it can significantly inhibit the growth of esophageal carcinoma. PMID: 31823702 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 13, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Safety Profiles and Pharmacovigilance Considerations for Recently Patented / Approved Anticancer Drugs.
Authors: Baldo P PMID: 31778105 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 30, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Apigenin, A Plant Flavone Playing Noble Roles in Cancer Prevention Via Modulation of Key Cell Signaling Networks.
CONCLUSION: This mini-review will explain the present research status of Apigenin and will further throw some light on how Apigenin performs its anti-cancerous actions by interfering with the key cell-signaling pathways. PMID: 31746310 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 22, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

MDM2-p53 Interaction Inhibitors: Current State of Art and Updated Patent Review (2010-present).
CONCLUSION: Novel MDM2 inhibitors thanks to higher potency and better ADME properties have shown effectiveness in preclinical and clinical development however the final improvement of therapeutic potential for MDM2 inhibitors might depend on the useful combination therapy and exploring new cancer and non-cancer indications. PMID: 31642413 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 24, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Chimeric Antigen Receptor-Engineered T-Cells - a New Way and Era for Lymphoma Treatment.
CONCLUSION: CAR T-cell therapy significantly improved the outcome of patients with relapsed or refractory diffuse large B-cell lymphoma. The advances in CAR T-cells production technology will improve the results and enable the expansion of this new immunotherapy. PMID: 31642414 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 24, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Mechanism of a Novel Camptothecin-Deoxycholic Acid Derivate Induced Apoptosis Against Human Liver Cancer HepG2 Cells and Human Colon Cancer HCT116 Cells.
Conclusion: These findings suggested that the apoptotis in both cell lines induced by G2 in both cell lines was related to both the extrinsic and intrinsic pathways. PMID: 31644410 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 24, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Association between hTERT Polymorphisms and Female Papillary Thyroid Carcinoma.
CONCLUSION: Our finding suggests that hTERT polymorphisms rs10069690 and rs2736100 are associated with increased risk for PTC in Chinese female population and rs2736100 may be related to age. Consistent with US20170360914 and US20170232075, they are expected to be potential molecular target for anti-cancer therapy. PMID: 31538903 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 22, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Tissue Distribution and Systemic Toxicity Evaluation of Raloxifene Targeted Polymeric Micelles of Poly (Styrene-Maleic Acid)-Poly (Amide-Ether-Ester-Imide)-Poly (Ethylene Glycol) Loaded With Docetaxel in Breast Cancer Bearing Mice.
CONCLUSION: The results indicate that RA-conjugated polymeric micelles may be a strong and effective drug delivery system for DTX therapy and uptake of drug into tumor cells, and overcome the disadvantages and side effects of conventional DTX. PMID: 31538904 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 22, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

HMGA and Cancer: A Review on Patent Literatures.
CONCLUSION: Powerful strategies able to selectively interfere with HMGA expression and function could represent a helpful approach in the development of new anti-cancer therapies. PMID: 31538905 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 22, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Advanced Thyroid Cancer.
CONCLUSION: It is essential to investigate the safety profile of the recent anticancer drugs for advanced thyroid cancer to allow health professionals to make the best choice for each patient by evaluating the risk/benefit assessment. PMID: 31362663 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - August 1, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma.
CONCLUSION: The new oncological therapies against melanoma are based on increasingly specific biological and immunological targets. For this reason, the potential toxicities that are expected from patients would be less relevant than the systemic "classical" chemotherapy. However, the new therapies are not free from the risk of causing adverse reactions, some of which must be managed promptly and appropriately; moreover the multiplicity of the metabolic pathways exposes the new target therapies to relevant potential interactions. This review can help to understand how important it is not to underestimate ...
Source: Recent Patents on Anti-Cancer Drug Discovery - August 1, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer.
CONCLUSION: Currently, a consistent number of new drugs and combinations have been introduced for the treatment of patients with advanced-stage lung cancer. Safety data remain essential to better assess the long-term risk/benefit ratio of these valuable emerging therapies. The new patents' development could provide further significant improvements for lung cancer treatment. PMID: 31362665 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - August 1, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

A truncated Snail1 transcription factor alters expression of essential EMT markers and suppresses tumor cell migration in a human lung cancer cell line.
CONCLUSIONS: Transfection of A549 cells with CSnail1 alters expression of essential EMT markers and consequently suppresses tumor cell migration. These findings confirm capability of CSnail1 in EMT blocking and in parallel to current patents could be applied as a novel strategy in prevention of metastasis. PMID: 31131753 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 29, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Inhibitory effect of hydroxysafflower yellow B on the proliferation of human breast cancer MCF-7 cells.
CONCLUSION: These data demonstrate that HSYB arrests the MCF-7 cell cycle at the S phase and induces cell apoptosis. Patent US20170246228 indicates that HSYB can be potentially used for the prevention and treatment of human breast cancer. PMID: 31096897 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 19, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Repurposing Disulfiram as an Anti-Cancer Agent: Updated Review on Literature and Patents.
CONCLUSION: For years the FDA-approved, well-tolerated, inexpensive, orally-administered drug Disulfiram was used in the treatment of chronic alcoholism, but it has recently demonstrated anti-cancer effects in a range of solid and hematological malignancies. Its combination with clinically relevant copper concentrations might overcome the resistance of many anti-cancer drugs in vitro, in vivo, and in patients. PMID: 31084595 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 16, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK.
Conclusion: Tumor tissue concentration-time curves of CPT-11 and SN-38 can be determined via PBPK modeling. Rate constants of enzymes and transporters can be shown for healthy and tumor bearing individuals. The results will throw light on the effective concentration of active compound at its target tissue at the clinically applied IV dose. PMID: 30760193 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - February 16, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

From Antimicrobial to Anticancer Peptides: The Transformation of Peptides.
CONCLUSION: These findings may have important clinical implications for cancer treatment, especially in patients with conditions that are not currently treatable by other drugs, or that are resistant to existing cancer drugs. PMID: 30663573 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 23, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Tocotrienols and Cancer: From the State of the Art to Promising Novel Patents.
CONCLUSION: The promising anti-cancer effects shown by TTs in several preclinical studies may open new opportunities of therapeutic interventions in different tumors. Thus, clinical trials aimed at confirming TTs chemopreventive and tumor-suppressing activity, particularly in combination with standard therapies, are urgently needed. PMID: 30652648 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 18, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment.
CONCLUSION: Powerful strategies able to selectively interfere with its expression and function should reveal helpful in the development of new anti-cancer therapies. PMID: 30652649 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 18, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.
CONCLUSION: This review summarizing antigens and approaches to overcome defects of CAR T cell immunotherapy from patents and publications might contribute to broad readership. PMID: 30636615 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 15, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Contemporary Formulations for Drug Delivery of Anticancer Bioactive Compounds.
CONCLUSION: The focus of recent research is not only to clarify the exact mechanisms of action and therapeutic effects, but also to answer the issue of suitable delivery systems that can transport sufficient doses of bioactive compounds to the desired target. PMID: 30636616 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 15, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

New Anti-Cancer Strategies in Testicular Germ Cell Tumors.
CONCLUSION: Finally, the pathogenesis of testicular germ cell tumor needs to be deeply understood so that it will improve data on stem cells, tumorigenesis and disease tumor management by more selective treatment. PMID: 30636617 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 15, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Tobacco Smoking: Risk to Develop Addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer.
CONCLUSION: Genetic studies highlight the involvement of nicotinic receptors variants in addiction, chronic obstructive pulmonary disease and/or lung cancer. A future important step will be to translate these genetic findings to clinical practice. Interventions able to help smoking cessation in nicotine dependence subjects, under patent, are reported. PMID: 30605063 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 4, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Lentiviral-Mediated Overexpression of MicroRNA-141 Promotes Cell Proliferation and Inhibits Apoptosis in Human Esophageal Squamous Cell Carcinoma.
CONCLUSION: miRNA-141 promotes cell proliferation and inhibits apoptosis in ESCC by down-regulating the expression level of YAP1 and SOX17, indicating that miRNA-141 may be a potential molecular target for the treatment of ESCC. PMID: 30599110 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - January 3, 2019 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Death-Associated Protein Kinase 1 As A Promising Drug Target In Cancer and Alzheimer's Disease.
CONCLUSION: DAPK1 plays a critical role in diverse physiological processes and importantly, its deregulation is implicated in the pathogenesis of either cancer or AD. Therefore, manipulating DAPK1 activity and/or expression may be a promising therapeutic option for cancer or AD. PMID: 30569876 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - December 22, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

High-throughput Strategy Accelerates the Progress of Marine Anticancer Peptide Drug Development.
Authors: Lyu P, Kwok HF Abstract PMID: 30474536 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 28, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Cucurbitacins as Anticancer Agents: A Patent Review.
CONCLUSION: The significant anticancer effects of natural and semi-synthetic cucurbitacins put them as new drug candidates. Moreover, cucurbitacins have the capability to form conjugates with other anticancer drugs which will synergistically enhance their anticancer effects. The authors believe that in order to get lead compounds, there should be a greater focus on the synthesis of homodimers, heterdimers, and halo derivatives of cucurbitacins. In the opinion of the authors the analysis of the published patents on the cucurbitacins indicates that these compounds can be developed into a regimen to treat a wide spectrum of c...
Source: Recent Patents on Anti-Cancer Drug Discovery - November 21, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents.
CONCLUSION: There is a strong tendency for the development of new nanostructured systems for the release of drugs; particularly, in recent years, the development of nanoparticles has focused on nanodiscs, gold nanoparticles and immunoliposomes. PMID: 30381087 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - November 2, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A review update of Patent Literature.
CONCLUSION: PD-1/PD-L1 inhibitors show significant anti-cancer responses as stand-alone agents and in combination with other cancer therapies. More efficient experimental studies and clinical trials are necessary to evaluate the host-tumor cells' interactions. Understanding the cancer microenvironment, identifying specific biomarkers and X-ray crystalline structures of PD-1/PD-L1 complexes, including molecular and genomic signature studies are essential to determine the feasibility of PD-1/PD-L1 inhibitors for development into drug-like cancer immunotherapeutics. PMID: 30370857 [PubMed - as supplied by publisher] (Sour...
Source: Recent Patents on Anti-Cancer Drug Discovery - October 30, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Patent Selections.
Authors: PMID: 30306846 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 13, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Acknowledgements to contributors.
ACKNOWLEDGEMENTS TO CONTRIBUTORS. Recent Pat Anticancer Drug Discov. 2018;13(4):479 Authors: PMID: 30306847 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - October 13, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Recent advances in developing novel anti-cancer drugs targeting tumor hypoxic and acidic microenvironments.
CONCLUSION: Developing more specific agents, and seeking sensitive, applicable and accurate biomarkers may improve the efficacy of drugs targeting hypoxic and acidic microenvironments. PMID: 30173649 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - September 5, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Journey describing the cytotoxic potential of withanolides: A patent review.
Authors: Hussain H, Csuk R, Green IR, Abbas G, Hussain W Abstract Withanolides are C-28 ergostane steroids known to demonstrate some very interesting therapeutic properties. Numerous withanolides have been isolated from a variety of different plant species and can be employed to treat various types of cancers. Withanolides are indeed capable of demonstrating excellent anticancer, anti-inflammatory, and neuroprotective activities. Additionally, libraries of prepared withaferin A analogs incorporating an acyl, sulphate, amide and aldehyde functionality have demonstrated the most potential response potentials. It is o...
Source: Recent Patents on Anti-Cancer Drug Discovery - August 10, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Semi-synthetic Derivatives of Heliomycin with an Antiproliferative Potency.
CONCLUSION: The patent claims a series of 4-aminomethyl derivatives of heliomycin as well as a pharmaceutical composition based on it. Application of Mannich aminomethylation allowed to diversify the structure of initial antibiotic and to obtain the derivatives with significantly improved water solubility and a potent antiproliferative efficacy. PMID: 30039764 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 25, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
CONCLUSION: In tumor cells, the stabilization of genomic machinery and self-directed death may be achieved via a balanced activation of the AF1 and AF2 domains of ERs by natural estrogen treatment. In contrast, the blockade of either AF1 or AF2 domain by endocrine disruptors leads to toxic symptoms and unforeseeable tumor responses. PMID: 30027855 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 23, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

CS5931, a novel marine polypeptide, inhibits migration and invasion of cancer cells via interacting with enolase 1.
CONCLUSION: Our present study showed that the recombinant CS5931 could inhibit tumor invasion and metastasis via interacting with enolase 1, suggesting that the new marine polypeptide CS5931 possesses the potential to be developed as a novel anticancer agent. PMID: 29956637 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - July 1, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Targeting Metabolism to Counteract Tumor Angiogenesis: A Review of Patent Literature.
Authors: Petrillo S, Tolosano E, Munaron L, Genova T Abstract Massive vessel recruitment is required to sustain rapid tumor growth by delivering oxygen and nutrients. Current strategies to counteract angiogenesis are mostly aimed at reducing tumor vessel density. However, many of these drugs have been shown to trigger hypoxia, thus exacerbating tumor aggressiveness. Promising results come from a completely different approach based on the "normalization" of the endothelial layer and the consequent improvement of the vascular function. Since endothelial metabolism has proved essential in the regulation of t...
Source: Recent Patents on Anti-Cancer Drug Discovery - May 31, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Patent Selections.
Authors: PMID: 29788867 [PubMed - in process] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 25, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Evolving strategies for the treatment of T-cell lymphoma: a systematic review and recent patents.
CONCLUSION: Therapeutic strategies based on better molecular characterization of various histological types are certain to be used in the future. PMID: 29769011 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 18, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Synthesis, in-silico and in-- vitro cytostatic activity of new lipophilic derivatives of hydroxyurea.
CONCLUSION: Compound 7 with the suitable volume, log p and shape is the more or most active ligand against both cell lines. It is concluded or suggested that the size, shape and hydrophobic character of substituents strongly affect the pharmacodynamics and pharmacokinetic of these type of ligands. PMID: 29769012 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 18, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research

Recent Progress of Marine Polypeptides as Anticancer Agents Marine Polypeptides as Anticancer Agents.
CONCLUSION: Marine peptides possess chemical diversity and displays potent anticancer activity via targeting different signal pathways. Some of the marine peptides are promising to be developed as novel anticancer agents. PMID: 29708076 [PubMed - as supplied by publisher] (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - May 2, 2018 Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research